P

Pfizer

Makes cancer drugs, vaccines and other medicines

Junior Clinical Research Associate

Full-TimePosted on 10/15/2026Deadline 10/22/26
No salary listed
Junior
Bachelor's
São Paulo, State of São Paulo, Brazil
RemoteSignificant travel (60–80%) within the area is required; some international and weekend travel may be required.
Biology & BiotechClinical Research Operations

About the job

Requirements
  • A bachelor's degree in life sciences or a professional degree in a life-sciences field, such as nursing, pharmacy, or medicine, or equivalent.
  • Knowledge of clinical-trial methodologies, ICH/GCP, FDA, and local-country regulations.
  • At least 1 year of relevant experience in clinical-research site monitoring and management.
  • Fluency in English and the native language or languages of the country of work.
  • Knowledge of clinical research and development processes and ability to gain command of process details.
  • Knowledge of global and local regulatory requirements.
  • Understanding of key operational elements of clinical research, including monitoring, data acquisition and cleaning, and reporting.
  • Knowledge of disease and technical areas pertaining to clinical studies, company direction, investigational products, and associated development plans.
  • Understanding of the region, country, culture, and medical practice and how they affect clinical-trial delivery.
  • Ability to work in a matrix team environment and influence, drive or lead, and work through others to deliver clinical trials successfully.
  • Ability to evaluate, interpret, and present complex issues and data to support risk management and mitigation.
  • Effective verbal and written communication skills when relating to colleagues and associates inside and outside the organization.
  • Significant travel (60–80%) within the area is required; some international and weekend travel may also be required.
Responsibilities
  • Manage and monitor assigned investigator sites to ensure proper conduct of clinical trials in accordance with the Study Monitoring Plan, applicable laws, Good Clinical Practices, and Pfizer standards, meeting project goals, timelines, and quality requirements.
  • Manage assigned operational aspects of clinical-trial implementation at investigator sites from site initiation through database lock, meeting timelines and quality deliverables.
  • Serve as the primary point of contact for assigned investigator sites during study conduct, partnering with or escalating to the Site Care Partner to ensure quality site delivery.
  • Interface with the study team as needed and facilitate information flow among study-team members, vendors, and investigator sites.
  • Partner with the Site Care Partner on investigator-site development, coaching, and training of site personnel to support protocol compliance and patient safety; provide protocol training and address site staff questions, including known or anticipated operational and clinical-trial risks.
  • Attend investigator meetings when required, virtually or face to face.
  • Support enrollment and address site-activation and recruitment issues; partner with the Site Care Partner and study team to define and support site-level recruitment initiatives.
  • Assess electronic-diary data remotely.
  • Conduct onsite and remote or electronic monitoring for site initiation, routine monitoring, and site closure in accordance with the Study Monitoring Plan and standard operating procedures, adapting to emerging issues and technologies.
  • Monitor site-level adverse events and serious adverse events; collaborate with the Drug Safety Unit and follow up with investigator sites as needed to resolve required serious-adverse-event report information.
  • Submit required reports, documentation, updates, and tracking within required timeframes, including Trial Master File documentation, site reports, follow-up letters, protocol deviations, patient recruitment, clinical supply management, study progress, and metrics.
  • Identify and resolve investigator-site issues within required timeframes; agree and develop corrective and preventive actions with investigators and site personnel to close issues and prevent recurrence or persistence.
  • Resolve data queries within required timelines, prepare investigator-site close-out plans, and conduct close-out activities within required timelines.
  • Oversee investigational products at investigator sites, including receipt, handling, accounting, storage conditions, and destruction.
  • Support database release as needed.
  • Undertake unblinded-monitor responsibilities when appropriate.
  • Maintain a thorough understanding of the product, protocol, and therapy area to support discussions with investigators and site teams.
  • Interact with investigator-site healthcare professionals in a manner that enhances Pfizer's credibility and scientific leadership and facilitates Pfizer's clinical-development goals.
  • Support the study clinician in ensuring patient safety and eligibility and providing clinical guidance to investigators.
  • Drive Quality Event submission and remediation when applicable.
  • Serve as a point of contact for audits and drive audit-observation corrective and preventive action development and checks when applicable.
Desired Qualifications
  • Therapeutic experience in oncology, vaccines, internal medicine, or infectious diseases is preferred.
  • Global clinical-trial experience is preferred.

About the company

Pfizer discovers, makes, and sells prescription medicines and vaccines for patients, doctors, and governments worldwide, with large businesses in vaccines, cancer, heart disease, and rare diseases. In 2020, its COVID-19 shot, developed with German partner BioNTech, became the first COVID-19 vaccine authorized in the United States. Its scientists find drug candidates and run clinical trials to prove they are safe and effective, and Pfizer then manufactures approved products in its own plants, earning most of its money from patented drugs before cheaper generic copies arrive. Pfizer was founded in 1849 as a chemicals business in Brooklyn and is based in New York City.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Get referred to Pfizer

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Newer drugs carry the business: launched and acquired products grew 18% operationally in Pfizer's August 2026 quarterly report.
  • The outlook improved: in August 2026, Pfizer raised its 2026 revenue guidance to $60.5 billion to $62.5 billion.
  • Vaccine scientists get room to grow: Pfizer's $470 million Pearl River, New York research expansion is designed for 370 workers.

What critics are saying

  • Expect more site cuts: in November 2025, Pfizer moved to shrink Swiss staff from about 300 to roughly 70.
  • Generics will erase sales: Pfizer expects patent losses to cut $17 billion to $18 billion of yearly revenue through 2028.
  • Pfizer is chasing obesity leaders: Metsera's monthly shot showed 12.3% weight loss at 28 weeks in February 2026 data.

What makes Pfizer unique

  • Pfizer bought its way into cancer: its Seagen buyout added antibody-drug conjugates, which carry chemotherapy straight to tumors.
  • Pfizer is betting on monthly obesity shots: Metsera's berobenatide is dosed once a month, unlike weekly Wegovy and Zepbound.
  • Pfizer leans on one partnered heart drug: blood thinner Eliquis, sold with Bristol Myers Squibb, brings about 14% of revenue.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Hybrid Work Options
  • Relocation Assistance

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-3%

2 year growth

-3%
Yahoo Finance
Oct 19th, 2026
Five low-beta dividend stocks: Pfizer yields 5.83%, Coca-Cola raises payout since 1999

Five defensive dividend stocks offer income with less volatility than the broader market, according to a 24/7 Wall St. analysis. All five have a beta well below 1, meaning they have historically moved less than the market. Pfizer leads with a forward yield of 5.83% at $29.49 a share. AT&T yields 4.77% at $23.27, and its $1.11 dividend uses about 42% of 2026 free cash flow guidance of $18B+. Debt of $144B is its main risk. Dominion Energy yields 4.24%, while Coca-Cola and Colgate-Palmolive each yield 2.27%. Coca-Cola has raised its dividend every year since 1999, and Colgate's next ex-dividend date is October 20, 2026.

Yahoo Finance
Oct 15th, 2026
GSK beats Pfizer as dividend stock: 39% payout vs 89% of free cash flow

GSK looks the better dividend stock than Pfizer, according to a comparison of the two drugmakers, which both face major patent losses before 2030. Pfizer yields 6.3% and GSK 4.1%. Over the twelve months to June 2026, Pfizer paid out 89% of its free cash flow in dividends ($9.79 billion of $10.98 billion), against 39% at GSK (£2.67 billion of £6.90 billion). Pfizer's chief executive officer, Albert Bourla, said the dividend will be maintained even in "the most stretched scenarios." Pfizer raised its 2026 revenue guidance to $60.5 billion to $62.5 billion. GSK raised its dividend 17.6% in fiscal 2025 after an earlier cut, and Q2 2026 sales rose 5%. Its main risk is debt: net debt rose to £22 billion after the Nuvalent acquisition.

Yahoo Finance
Oct 14th, 2026
Pfizer's 6% dividend pays investors to wait as oncology pipeline drives growth beyond COVID-19

Pfizer offers a dividend yield of just over 6% while it builds growth beyond its COVID-19 products. The drugmaker declared a quarterly dividend of $0.43 in June 2026, its 351st consecutive quarterly payment. In the second quarter, revenue from launched and acquired products rose 18% year over year. Pfizer raised the midpoint of its full-year guidance, helped by stronger non-COVID sales from drugs such as Eliquis, Padcev, and Vyndaqel. Oncology is the next focus. Pfizer is investing in antibody-drug conjugates and bispecific antibodies, and it entered a global collaboration with Innovent Biologics covering 12 early-stage cancer programs. Not every experimental drug will succeed, but a broader pipeline improves the odds. If new medicines work, the share price could rise on top of the dividend income.

Yahoo Finance
Oct 13th, 2026
Six high-yield dividend stocks fail the payout test, from Ford to Whirlpool's 9.37% mirage

High dividend yields can hide weak payouts, and a four-step test helps separate real income from traps. It checks earnings with one-offs stripped out, full-year free cash flow against dividends, management's explanation, and whether debt funds the gap. Ford yields 4.99% and shows a trailing EPS of -$1.88, caused by $4.2B in one-time charges. Its debt-to-equity of 4.66 leaves the $0.60 dividend exposed to a downturn. Pfizer yields 6.03%, but its free cash flow yield is 5.60%. Clorox's roughly $405M of free cash flow fell short of about $601M in dividends. Whirlpool fails every step. It cut its quarterly dividend from $1.75 to $0.90 in 2025, paid no common dividend in the second quarter of 2026, and its shares are down 59.48% since the end of 2025. 3M and Dow pass, with payouts now covered by cash.

Yahoo Finance
Oct 12th, 2026
UPS, Pfizer, Kraft Heinz and Ford dividends at risk as payouts outstrip earnings

Four blue chip companies, UPS, Pfizer, Kraft Heinz, and Ford, may struggle to sustain their dividends, according to an analysis of their earnings, cash flow, and debt. UPS yields 7.02% and pays out about 121% of its GAAP earnings. Pfizer yields 6.10%, with a GAAP payout ratio of about 226%; its 2025 free cash flow of $9.076 billion fell short of $9.771 billion in dividends. Kraft Heinz yields 6.82%, but its trailing GAAP earnings per share are −$2.88 after $7.4 billion in impairments. Ford yields 4.98% after an $8.162 billion loss in 2025, and its debt-to-equity ratio is 4.66. All four companies say their payouts are safe, and each points to adjusted earnings guidance that covers the dividend.